RU2009102512A - Терапевтические соединения - Google Patents

Терапевтические соединения Download PDF

Info

Publication number
RU2009102512A
RU2009102512A RU2009102512/04A RU2009102512A RU2009102512A RU 2009102512 A RU2009102512 A RU 2009102512A RU 2009102512/04 A RU2009102512/04 A RU 2009102512/04A RU 2009102512 A RU2009102512 A RU 2009102512A RU 2009102512 A RU2009102512 A RU 2009102512A
Authority
RU
Russia
Prior art keywords
pain
disease
caused
cancer
inflammation
Prior art date
Application number
RU2009102512/04A
Other languages
English (en)
Russian (ru)
Inventor
Эдвард Дэниел СЕЙВОРИ (GB)
Эдвард Дэниел СЕЙВОРИ
Original Assignee
Биовитрум Аб (Пабл) (Se)
Биовитрум Аб (Пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовитрум Аб (Пабл) (Se), Биовитрум Аб (Пабл) filed Critical Биовитрум Аб (Пабл) (Se)
Publication of RU2009102512A publication Critical patent/RU2009102512A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
RU2009102512/04A 2006-06-27 2007-06-26 Терапевтические соединения RU2009102512A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0601396-5 2006-06-27
SE0601396 2006-06-27
US83730806P 2006-08-11 2006-08-11
US60/837,308 2006-08-11

Publications (1)

Publication Number Publication Date
RU2009102512A true RU2009102512A (ru) 2010-08-10

Family

ID=38545430

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009102512/04A RU2009102512A (ru) 2006-06-27 2007-06-26 Терапевтические соединения

Country Status (12)

Country Link
US (1) US7906518B2 (enExample)
EP (1) EP2066685B1 (enExample)
JP (1) JP2009541436A (enExample)
CN (1) CN101479290A (enExample)
AT (1) ATE500263T1 (enExample)
AU (1) AU2007263726A1 (enExample)
BR (1) BRPI0713901A2 (enExample)
CA (1) CA2657973A1 (enExample)
DE (1) DE602007012904D1 (enExample)
ES (1) ES2361886T3 (enExample)
RU (1) RU2009102512A (enExample)
WO (1) WO2008000743A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064671A1 (en) * 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2010080540A1 (en) * 2008-12-18 2010-07-15 Inspire Pharmaceuticals, Inc. Method for treating inflammatory conditions
RU2478391C2 (ru) * 2011-05-20 2013-04-10 Евгений Петрович Измайлов Способ физиотерапевтического и консервативного лечения плеврита
RU2478392C2 (ru) * 2011-05-20 2013-04-10 Евгений Петрович Измайлов Способ консервативного и физиотерапевтического лечения серозно-геморрагического плеврита
BR112015002249A2 (pt) * 2012-08-01 2017-07-04 Lewis And Clark Pharmaceuticals Inc composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
US11541071B1 (en) * 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
ES2194320T3 (es) 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
CA2533402A1 (en) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
JP2007500689A (ja) * 2003-07-31 2007-01-18 サノフイ−アベンテイス アミノキノリン誘導体およびアデノシンａ３リガンドとしてのそれらの使用
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
DE602004027409D1 (de) * 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
JP2007509180A (ja) * 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
KR20070004792A (ko) * 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
JP2007536241A (ja) * 2004-05-03 2007-12-13 ユニバーシティ オブ バージニア パテント ファウンデーション 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト
EP1781101A2 (en) * 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
KR20070050484A (ko) * 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ａ1 및 ａ3 아데노신 수용체 아고니스트로서의 퓨린 유도체
US8461128B2 (en) * 2005-04-15 2013-06-11 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
US7514417B2 (en) * 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
DK1983990T3 (da) * 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
CA2644996A1 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CA2646333C (en) * 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
US7691869B2 (en) * 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
US20080312160A1 (en) * 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
WO2009006046A1 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド Ａ３アデノシン受容体アンタゴニスト
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
CA2714516A1 (en) * 2008-02-07 2009-08-13 Gilead Palo Alto, Inc. Abca-1 elevating compounds and the use thereof

Also Published As

Publication number Publication date
BRPI0713901A2 (pt) 2013-01-08
EP2066685B1 (en) 2011-03-02
ES2361886T3 (es) 2011-06-24
CA2657973A1 (en) 2008-01-03
JP2009541436A (ja) 2009-11-26
ATE500263T1 (de) 2011-03-15
US20080027081A1 (en) 2008-01-31
WO2008000743A3 (en) 2008-02-21
WO2008000743A2 (en) 2008-01-03
CN101479290A (zh) 2009-07-08
DE602007012904D1 (de) 2011-04-14
US7906518B2 (en) 2011-03-15
AU2007263726A1 (en) 2008-01-03
EP2066685A2 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
CN101189234B (zh) Hcv的杂二环抑制剂
RU2405783C2 (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
JP2007526291A5 (enExample)
JP2007526291A (ja) アデノシン受容体アゴニスト
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
JP2009541436A5 (enExample)
RU2009102531A (ru) Терапевтические соединения
US7906518B2 (en) Therapeutic compounds
WO2016130271A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
JP2009541438A5 (enExample)
JP2011520864A (ja) 置換キナゾリン
TWI638825B (zh) 抑制癌症及病毒之化合物
CN117241803A (zh) 嘌呤核苷、其中间体和其制备方法
RU2009102536A (ru) Терапевтические соединения
JP2011520865A (ja) 置換キナゾリン
JP5185823B2 (ja) がん治療用ジオキソラン誘導体
RU2837221C1 (ru) Новые производные пирролопиримидинов
RU2837216C1 (ru) Новые производные пирролопиримидинов
JP2023545414A (ja) Ｈｅｒ２の強力かつ選択的な阻害剤
RU2850228C1 (ru) Способ получения новых производных пирролопиримидинов
RU2850268C1 (ru) Способ получения новых производных пирролопиримидинов
RU2850232C1 (ru) Способ получения новых производных пирролопиримидинов
RU2850229C1 (ru) Способ получения новых производных пирролопиримидинов
CN114149457B (zh) 一种苯并[c][1,2]氧杂硼戊环-1(3H)-醇类合物及其用途
RU2837215C1 (ru) Новые производные пирролопиримидинов

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20111004